Current page location

Genome Editing Research Center

Genome Editing Research Center
Objectives
Research on gene function using genome editing technology
  • Development and upgrade of genome editing technology
  • Research on gene function and gene therapy using genome editing technology
  • Production of transformation mouse model using genome editing technology
Researcher
    Click on the name
researchers and research statement
name research fields
Yong Sam Kim
/ Associate Director
  • Development of new genome editing technology
  • Research on the upgrade of genome editing technology
Yong Sung Kim
/ Principal Researcher
  • Exploration of epigenetic target gene related to cancer and stem cell differentiation
  • Development of epigenetic editing technology for target gene
Byoung-Mog Kwon
/ Principal Researcher
  • Exploration of gene related to diseases using chemical biology and chemical genome and findoug out the function using genome editing technology
Jeong Heon Ko
/ Principal Researcher
  • Research on the function of saccharide gene and development of saccharide genome editing technology
Namshin Kim
/ Senior Researcher
  • Integration of data and multi-dimensional analysis of information related to NGS based genome,
  • Analysis on NGS based animal and plant’s de novo assembly and whole genome information
Seon-Young Kim
/ Principal Researcher
  • Research on the understanding of cancer in human body through functional genome approach
  • Bioinformatics and computational biology
Dae Yeul Yu
/ Principal Researcher
  • Production of transformation mouse model and functional research
Kyou Hoon Han
/ Principal Researcher
  • Disordered protein, NMR structural biology, anticancer nano new drug
Yoonkyung Kim
/ Senior Researcher
  • Biocompatible macromolecules, dendrimers, nanomedicine (diagnosis, drug delivery), organic/supramolecular/medicinal chemistry
Jeong Gu Kang
/ Senior Researcher
  • Development of epigenetics regulation method of target gene using genome editing technology
research areas
  • Research on the upgrade of genome editing technology
    • Research on the improvement of efficiency for CRISPR/Cas9 and CRISPR/cpf1 genome editing technology
    • Establishment of target regulation system of genes related to stem cell, disease and aging
  • Development of human mimicking mouse model using saccharide genome editing technology
    • Selection of saccharide gene that causes differences of saccharide between human and mouse and development of mouse model with modification of the gene.
    • Verification of non clinical appropriateness of human mimicking mouse
  • Development of new genome editing technology
    • Development and verification of effectiveness for the 4th generation genome editing technology
  • Development of mouse model of diseases using animal transformation technology
  • Research on the mechanism of antioxidant enzyme in the cancer development process
  • Finding the biologically active mechanism of disordered protein and mechanism of causing disease
  • Design, synthesis, and application of new organic macromolecules or nano-sized compounds for the diagnosis and treatment of intractable diseases
Achievements
  • Induction of selective expression of target genes using genome editing technology
    • Development of gene expression regulation system based on TALEN targeting E-cadherin promoter
  • Development of epigenetic regulation method of target gene
    • Development and verification of technology that induces epigenetic transformation specific to a certain chromatin structure
  • Development of mouse model of various disease including liver and lung cancer
  • Finding the area of activated PreSMo of disordered protein for the first tie and spread the idea to the world
  • Development of new nano-sized dendritic compounds for diagnostic imaging of cancer and retinal diseases
Outstanding Papers
  • Yong-Sam Kim (corresponding) Mol Cell Proteomics. 14(3):782-95.
    • Semi-quantitative measurement of a specific glycoform using a DNA-tagged antibody and lectin affinity chromatography for glyco-biomarker development.
  • Jeong Gu Kang (co-first) Oncotarget. 15;6(27):23837-44.
    • Direct regulation of E-cadherin by targeted histone methylation of TALE-SET fusion protein in cancer cells.
  • Byoung-Mog Kwon (corresponding) Biochemical Pharmacology. 97:38-50.
    • Sugiol inhibits STAT3 activity via regulation of transketolase and ROS-mediated ERK activation in DU145 prostate carcinoma cells.
  • Dae-Yeul Yu (Corresponding) Oncogene. 2015 Oct 26
    • Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway.
  • Kyou-Hoon Han (corresponding) J. Biol. Chem.. 275:29426-29432.
    • Local Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53 (pioneering work on IDPs. citation > 220 times)
  • Yoonkyung Kim (corresponding) Angew. Chem. Int. Ed. 51(12):2878-82.
    • High-contrast reversible fluorescence photoswitching of dye-crosslinked dendritic nanoclusters in living vertebrates.